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Objectives. The objectives of this study were to elicit health utility scores for moderate Alzheimer’s disease (AD) using members of
the general public. Methods. Five-hundred Canadians were chosen randomly to participate in a telephone interview. The EQ-5D
was administered to estimate the health utility score for respondents’ current health status (i.e., no AD) and for a hypothetical
moderate AD health state. Regression analyses were conducted to explain the perceived utility decrement associated with AD.
Results. The mean age of the respondents was 51 years, 60% were female, and 42% knew someone with AD. Respondents’ mean
EQ-5D scores for their current health status and a hypothetical moderate AD were 0.873 (SD: 0.138) and 0.638 (SD: 0.194),
respectively (P<0.001). Age, gender, and education were signiﬁcant factors explaining this decrement in utility. Conclusion.
Members of the general public may serve as an alternative to patients and caregivers in the elicitation of health-related quality of
life in AD.
1.Introduction
Alzheimer’sdisease(AD),themostcommonformofdemen-
tia,istheﬁfthleadingcauseofdeathintheUnitedStates(US)
among persons aged 65 years or older [1]. Approximately 5.3
million Americans have AD, 5.1 million of whom are over
the age of 65 years [2]. The ﬁnancial burden of AD and other
dementias is considerable, with an estimated annual total
cost of $148 billion in the US in 2005 [3]. The annual cost
per patient in the US was found to be three times higher for
persons with AD and other dementias relative to persons
without AD or other dementias (i.e., $33,007 relative to
$10,603 in 2004) [3]. Other studies conducted in the US or
elsewhere similarly concluded that AD costs were high and
likely to rise over time due to the aging of the population [4–
7].
Although several medications have been approved to
treat AD (e.g., cholinesterase inhibitors, memantine), some
jurisdictions (e.g., United Kingdom [8], Ontario, Canada
[9]) limit reimbursement of these drugs (e.g., reimburse-
ment in theUnited Kingdom is limited to personswithmod-
erate AD only). The most prominent reasons for limiting
reimbursementaregroundedinthefactthatthemedications
treat the symptoms of AD only (they are not a cure) [10]
and cost between $2.90 and $6.80 per pill (US ﬁgures)
[11]. In a cost-containment environment, economic evalu-
ations are playing an increasingly important role in pricing
and reimbursement decisions, [12], especially for relatively
expensive medications that have modest eﬃcacy.
In AD, cognitive decline continues when persons with
the disease take cholinesterase inhibitors or memantine [10].
Consequently, an important outcome to consider when2 Journal of Aging Research
assessing these drugs in economic evaluations is health-
related quality of life (HRQoL). In economic evaluations,
HRQoL is usually expressed as part of a quality-adjusted life
y e a r( Q A L Y ) .AQ A L Yi sac o m p o s i t em e a s u r eo fo u t c o m e
where utilities for health states (expressed on a 0-1 scale
where 0 corresponds to death and 1 to perfect health) act as
qualitative weights to combine the quantity and quality of
life. Utilities can also be negative as some health states may
be considered worse than death.
The primary means of eliciting utilities in AD is to
administer a HRQoL questionnaire to patients or their care-
givers (acting as patient proxies) and convert the resulting
ratingsintohealthutility scoresusingascoringalgorithm.At
least two instruments, the quality of life-Alzheimer’s disease
(QoL-AD) [13] and dementia quality of life (DEMQOL)
[14], have been developed to assess AD patients’ HRQoL.
Both instruments have been tested in caregiver proxies and
baseline norms for a nondiseased population have been
developed for the QoL-AD [15]. However, neither instru-
ment has a scoring algorithm that can be used to convert
HRQoL ratings into health utility scores. For these reasons,
generic utility instruments such as the EuroQoL (EQ-5D)
[16] and the Health Utility Index (HUI) [17] have also
been used to elicit HRQoL for AD patients. These instru-
ments have scoring algorithms that allow HRQoL ratings
to be transformed into health utility scores. These generic
measures are often preferred to disease-speciﬁc measures in
economic evaluations for policy making to facilitate com-
parisons across diseases by using benchmarks (e.g., $50.000
per QALY gained).
Several studies have shown that the EQ-5D [18–23]a n d
the HUI [21, 22] may be used to reliably elicit utilities
in mild-to-moderate AD patients. However, a number of
studies [18, 20, 22, 24] also reported that some mild-to-
moderate AD patients would rate their health as perfect (i.e.,
utility score of 1) which could be due to patients’ lack of
insight about their impairment [22, 25]. In addition, many
AD patients do not consider themselves sick or suﬀering
from AD [21]. To avoid the challenges of patient-measured
HRQoL in AD, caregivers have been used as proxies to
measure HRQoL for persons with AD. In such cases, care-
givers complete instruments like the EQ-5D or the HUI on
behalf of patients. Comparisons suggest caregivers’ mean
proxy health utility scores for patients are lower than
patients’ self-reported health utility scores on both the EQ-
5D and HUI [19, 24, 26–28]. These diﬀerences may be due
to the inﬂuence of caregiver-speciﬁc issues such as burden,
whichmaybeespeciallyimportantwhencaringformoderate
AD patients. One study of the EQ-5D and HUI reported
that caregivers’ proxy HRQoL ratings were associated with
theirownlevelsofburden,ratherthanpatients’self-reported
HRQoL ratings or patients’ scores on the Mini-Mental State
Examination[29]forcognitiveimpairment[24].Conversely,
the authors of the same study wrote that caregivers’ proxy
ratings on the EQ-5D or HUI are at least as reliable as pa-
tients’ own ratings on these scales.
The equivocal results in patients and caregivers suggest
the need to search for other viable options that may be used
toobtainestimatesofADpatients’HRQoLandhealthutility.
One option that has not been explored in the literature to
date is to use the general public as a proxy to elicit HRQoL
for AD patients. This alternative may be especially relevant
for healthcare systems ﬁnanced in whole or in part by public
taxation (e.g., United Kingdom, Canada).
The ﬁrst step in assessing the usefulness of the general
public as a proxy is to determine whether the general public’s
HRQoL ratings would be sensitive to AD as a disease entity.
That is, would the general public assign diﬀerent HRQoL
ratings to an AD disease state relative to a non-AD disease
state? We had the opportunity to conduct a pilot study to
address this question by using data collected for a project
investigating Canadians’ level of support for a tax increase
to fund unrestricted access to AD medications [30]. In the
taxation study, we conducted a telephone survey of 500
randomly-selected members of the Canadian general public
who did not have AD. Part of the survey involved the
administration of the EQ-5D. Participants were asked to
complete the EQ-5D for their current health state and again
for a health state of moderate AD. Although it is possible
to derive utilities from the general public through direct
measurementsusingeitherastandardgamble(SG)approach
(iteratively ﬁnd the probability p in which the individual is
indiﬀerent between living with an hypothetical “moderate
AD” forever or taking a drug which can cure or kill him
with the probability p) or a time trade-oﬀ (TTO) approach
(hypothetically live with “moderate AD” forever or live
shorter in a better state of health); these methods are more
resource intensive and complicated to implement than the
administration of a preexisting questionnaire (e.g., EQ-5D).
For these reasons, respondents were asked in this pilot study
to answer the EQ-5D under a hypothetical “moderate AD”
health state.
Findings suggesting that the general public can act as
a proxy rater for AD patients’ HRQoL have important
implications for research. Recruitment of a random sample
of the general public is easier than recruiting a sample of
AD patients or caregivers. Regional or national rosters of
patientsorcaregiversdonotexist,soresearchinvolvingthese
persons often faces the challenge of recruiting subjects from
a patchwork of advocacy organizations, support groups,
and medical practices. If the general public can be used in
place of patients or caregivers, then there would be a clear
eﬃciencygainforresearcherswhowishtodetermineHRQoL
and health utilities for AD patients. Such a gain would be
important for analysts conducting economic evaluations in
response to rapidly changing policy environments.
2.MaterialsandMethods
2.1.StudyDesignandPopulation. Usingrandomdigitdialing
methodology, 500 adult members of the Canadian general
public were chosen to participate in a 15–20-minute tele-
phone interview. The sample was national in scope and
stratiﬁed by ﬁve household income categories before tax
(i.e., less than $20.000; $20.000 to less than $40.000; $40.000
to less than $60.000; $60.000 to less than $80.000; $80.000
or more). One hundred participants were included in eachJournal of Aging Research 3
stratum.Westratiﬁedbyincomecategoriestoavoidselection
bias on the tax support questions [30].
For the current paper, survey responses were weighted
[31] using income distributions from Statistics Canada to
ensure that the results were representative of the Canadian
populationintermsofincomedistribution.Forexample,the
2006 Canadian Census indicated that 6.86% of the Canadian
population had a total household income before tax of
less than $20.000, [32] compared to 20% in our sample.
In comparison, the higher household income category (≥
$80.000 per year) was underrepresented in our sample (20%
versus 39% in Canada). The composition of our sample
was almost representative of the Canadian population for
the three other household income categories (i.e., 18.02%
of Canadians had a total household income before tax
between$20.000to$40.000;19.34%ofCanadianshadatotal
household income before tax between $40.000 and $60.000;
17.10% of Canadians had a total household income before
tax between $60.000 and $80.000).
2.2. Data Collection. Data were collected using a structured
computer-assisted telephone interview (CATI). During the
interview, participants were asked to answer general ques-
tions about sociodemographics, knowledge of AD, health-
related quality of life, and whether they knew someone with
AD. Further details of the study methodology have been
published elsewhere [30].
2.2.1. Sociodemographics. Several variables were collected to
control for sociodemographics diﬀerences between partici-
pantsintermsofage,gender,income,education(highschool
or less; at least some technical or community college; at least
some university), and employment (not working, working,
or retired).
2.2.2. Awareness of AD. AD awareness was measured in two
ways. At study time, the Alzheimer’s Disease Knowledge Test
(ADKT) [33] was the only questionnaire to measure AD
awareness. The ADKT includes ﬁve true or false statements
(e.g., AD is a normal part of getting older, like gray hair and
wrinkles: true or false?). Higher scores on this questionnaire
representabetterknowledgeofAD.InadditiontotheADKT,
participants were asked if they knew friends or relatives with
AD.
2.2.3. Health-Related Quality of Life. The EQ-5D was used
to measure HRQoL. The EQ-5D is a validated, generic
HRQoL questionnaire that measures health status in terms
of ﬁve dimensions: mobility, self-care, usual activity, pain/
discomfort, and anxiety/depression. The EQ-5D was devel-
oped to be self-administered, but it has been successfully
usedintelephonesurveysofcaregiverburdeninAD[34]and
chronic diseases in Canada [35]. Although single dimension
scores are not available, the EQ-5D provides a weighted
health utility score based on population values, ranging from
0 (death) to 1 (perfect). The United States population-based
preference weights [36] were applied to the ﬁve EQ-5D
questionstogeneratetheEQ-5Dhealthutilityscore.TheEQ-
5D questionnaire also includes a visual analogue scale (VAS)
with anchors of 100 being the best imaginable state of health
and0 being theworstimaginablestateofhealth. Ascore(i.e.,
0–100%) from this self-rated “feeling thermometer” can be
computed to indicate the subject’s own assessment of their
health state.
The EQ-5D was administered twice in the study. First,
participants were instructed at the beginning of the study to
answer the EQ-5D thinking of their own health state at the
time of the interview. After 10 to 15 minutes of questions
to determine respondents’ support for a tax increase to
fund unrestricted access to AD medications, the following
deﬁnition of moderate AD was verbally described to the
participants: “Alzheimer’s disease is a progressive illness that
causes memory loss and other cognitive deﬁcits, advancing to
major personality changes and eventual loss of control over
bodily functions. In the moderate, mid-stage of Alzheimer’s
disease, mental abilities decline, personality changes, and
physical problems develop so that the person becomes more and
more dependent on caregivers”[ 37]. After this description,
participants were asked to answer the EQ-5D again, this time
imagining they had moderate AD. We computed diﬀerences
inhealthutilityscoresassociatedwiththecurrenthealthstate
and the hypothetical AD state. This allowed us to calculate
the perceived decrement in utility due to AD (i.e., diﬀerence
between utilities associated with one’s own health state and
the hypothetical AD state).
2.3. Statistical Analyses. Continuous variables (e.g., age,
income) were summarized using mean values and standard
deviations. Discrete variables (e.g., gender, education) were
summarized using percentages. The paired t-test was used
to determine if diﬀerences in utility or VAS scores between
the current health state and the hypothetical moderate AD
state were signiﬁcant. Statistical signiﬁcance of diﬀerences
between independent subgroups (e.g., comparing character-
istics of those answering the EQ-5D assuming AD versus
those who did not) was assessed using the t-test and Pear-
son’s chi-squared statistical test for continuous and discrete
variables, respectively.
Regression analyses were conducted to gain a better
understanding of the determinants of the EQ-5D utilities.
Because utility data are often nonnormal, with a ceiling
eﬀect at 1, we used a model based on ordinary least squares
(OLS) regression, coupled with bootstrap robust standard
errors, to analyse the utility data [38]. When modelling the
health utility score associated with the current health state of
respondents, age, gender, education, and income categories
were used as covariates. The score from the AD knowledge
test and whether participants know someone with AD
were also included as covariates because these factors may
inﬂuence one’s perception of a moderate AD health state. All
descriptive statistics and regression outputs are presented in
terms of weighted results. For comparison purposes, we also
present the unweighted results for participants’ sociodemo-
graphics characteristics.
The study received ethics approval from the Hamil-
ton Health Sciences/McMaster Faculty of Health Sciences
Research Ethics Board (Reference no. 08–179).4 Journal of Aging Research
Table 1: Characteristics of participants (unweighted and weighted
samples).
Sample characteristics Unweighted sample Weighted
sample
Gender n %%
Female 305 61 60
Male 195 39 40
Annual household
income
<$20.000 100 20 7
$20.000 to <$40.000 100 20 18
$40,000 to <$60.000 100 20 19
$60.000 to <$80.000 100 20 17
≥$80.000 100 20 39
Education
High school or less 169 34 26
At least some
technical or community
college
143 29 30
At least some university 184 37 44
Missing 4 <1 <1
Employment status
Not working
(unemployed,
student, homemaker)
66 13 10
Retired 142 28 24
Employed (full or
part time) 281 56 64
Missing 11 2 2
Participant knows a family member or close friend with
Alzheimer’s disease
Yes 211 42 42
No 286 57 57
Missing 3 1 1
3. Results
3.1. Study Participants. Table 1 presents participants’ un-
weighted and weighted sample characteristics. Starting with
the unweighted results, the mean age of the unweighted
sample was 51.8 years (median age: 51.0 years). Most were
female (61%) and working (56%), and 37% had at least
some university education. Forty-two percent of the sample
reportedthattheyknewafamilymemberorclosefriendwith
AD. As the sample was weighted to have more individuals
in the highest income category and less in the lowest
income category, higher education and employment rates
were observed in our weighted sample. No diﬀerences were
observed between the unweighted and the weighted sample
in terms of average age (i.e., 51.8 versus 50.6, resp.,) gender,
or knowing someone with AD (Table 1).
3.2. AD Awareness. T h em e a nw e i g h t e dA D K Ts c o r ew a s3 . 4
(SD: 1.0) out of 5 (higher scores indicate better knowledge
of AD). This reﬂects the fact that the majority of the
participants answered 4 out of 5 ADKT questions correctly.
However, as shown in Figure 1, almost 60% of participants
wrongly thought that depression following the death of a
husband or wife was similar to AD. No statistical diﬀerences
were found in the ADKT score between participants who
knewsomeonewithAD(i.e.,3.5)andthosewhodidnot(i.e.,
3.4). The mean unweighted score was similar to the weighted
score, that is, 3.4 (SD: 1.1).
3.3. EQ-5D Health Utility Score and Visual Analog Scale
(VAS). Forthefullsample(i.e.,n = 500),theweightedmean
EQ-5D utility score for participants’ self-assessed current
health state was 0.875 (SD: 0.137) and the mean VAS score
was 80.79. Unweighted mean scores were 0.857 and 79.16,
respectively.
While 99% of all participants were able to rate their
current health state on the EQ-5D, approximately 14% of
participants were unable to answer all ﬁve EQ-5D questions
for a hypothetical, moderate AD health state. In total, health
utility scores for a moderate AD health state were calculated
for 431 participants (i.e., 86%). When participants with
complete (n = 431) or incomplete EQ-5D (n = 69)
values were compared, only age was found to be signiﬁcantly
diﬀerent. Participants with missing data were older than
participants with nonmissing data (56.0 years of age versus
49.7 years of age, P = 0.0011).
Figure2presentsthemeanweightedEQ-5Dhealthutility
score and VAS scores for the current health state and the
hypothetical moderate AD health state for the 431 and 467
participantswithcompleteEQ-5DutilityscoreandVASdata,
respectively. The weighted EQ-5D health utility score for
current health state was 0.873 (SD: 0.138) and 0.638 (SD:
0.194) for a hypothetical moderate AD health state (versus
unweighted means of 0.856 and 0.639, resp.). The diﬀerence
between the current health state and the hypothetical health
state were statistically signiﬁcant (P<0.0001) in both
the weighted and unweighted cases. The utility decrement
associated with moderate AD was 0.235 for the weighted
results and 0.217 for the unweighted results.
Four hundred and sixty seven participants (93% of all
participants) answered the VAS for the current health state
and the hypothetical health state. On a scale from 0 to 100,
the weighted VAS scores decreased signiﬁcantly from 80.88
(current health state) to 57.10 (moderate AD health state)
(P value < 0.0001). The unweighted VAS scores were 79.38
and 57.70, respectively (P value < 0.0001). As shown in
Table 2, participants perceived they would have reductions
in mobility, self-care, and usual activities, as well as more
depression, when in a state of moderate AD.
3.4. Regression Analyses. Table 3 presents the results of the
two regression analyses used to identify the determinants
of the utility scores associated with the current health state
andthehypotheticalmoderateADhealthstate.Inexplaining
the current health state, age and income categories were
signiﬁcant variables, while education and gender were not.
Utility decreased with age and increased with income. When
analyzingtheutilitydecrementassociatedwithmoderateADJournal of Aging Research 5
Table 2: Domains of EQ-5D: current and hypothetical moderate AD health state (weighted results).
Domains/questions Current health state (N = 431) Assuming AD (N = 431)
Mobility
I have no problems in walking about 85.92% 42.80%
I have some problems in walking about 14.08% 55.97%
I am conﬁned to bed 0% 1.23%
Self-care
I have no problems with self-care 96.69% 27.12%
I have some problems washing or dressing myself 3.31% 71.13%
I am unable to wash or dress myself 0.0% 1.75%
Usual activities
I have no problems with performing my usual activities 82.67% 16.68%
I have some problems with performing my usual activities 15.67% 72.84%
I am unable to perform my usual activities 1.66% 10.48%
Pain/discomfort
I have no pain or discomfort 52.77% 42.14%
I have moderate pain or discomfort 45.20% 55.78%
I have extreme pain or discomfort 2.02% 2.09%
Anxiety/depression
I am not anxious or depressed 75.61% 18.73%
I am moderately anxious or depressed 22.78% 56.96%
I am extremely anxious or depressed 1.61% 24.31%
Table 3: Regression analyses: EQ-5D utility score and perceived utility decrement associated with a hypothetical moderate AD health state
(weighted results).∗
Variable Category
EQ-5D health utility score self-assessed current
health state
Utility decrement associated with moderate AD
health state
Coeﬃcient Bootstrap SE∗ Coeﬃcient Bootstrap SE∗
Intercept — 0.8308 0.0349 0.2650 0.0580
Age Years −0.0014 0.0004 −0.0035 0.0007
Gender Female
versus male 0.0170 0.0131 0.0480 0.0218
Some college
Versus high
school or
less
−0.0030 0.0201 0.0441 0.0297
Some university
Versus high
school or
less
0.0329 0.0194 0.0784 0.0256
Income: $20 to 40K Versus less
than $20K 0.1019 0.0256 0.0254 0.0349
Income: $40 to 60K Versus less
than $20K 0.0841 0.0258 −0.0062 0.0361
Income: $60 to 80K Versus less
than $20K 0.0999 0.0267 0.0504 0.0368
Income: $80K and + Versus less
than $20K 0.1065 0.0279 0.0479 0.0333
Know someone with
AD
Versus not
knowing ——0.0032 0.0215
ADKT score — ——0.0107 0.0099
Multiple R-squared 0.1028 0.1415
Adjusted R-squared 0.0877 0.1208
∗Bold indicates statistical signiﬁcance (i.e. P<0.05).6 Journal of Aging Research
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(%)
Percentage of correct answers to the Alzheimer’s disease awareness
True or false: Alzheimer’s disease is a normal part of
getting older, like gray hair and wrinkles
(“false” answer to each of the following statements is the
“correct” answer)
True or false: when the husband or wife of an older person
dies, the surviving spouse may su er from a kind of
depression that looks like Alzheimer’s disease
True or false: stuttering is an inevitable part of Alzheimer’s
disease
True or false: an older man is more likely to develop
Alzheimer’s disease than an older woman
True or false: nursing home expenses for Alzheimer’s
disease patients are covered by the government
Figure 1: Alzheimer’s disease knowledge test (ADKT) (weighted results).
0.873∗
0.8088∗
0.638
0.571
0
0.1
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0.4
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0.7
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0.9
1
EQ-5D utility score (N = 431) EQ-5D VAS (N = 467)
Current health state
Hypothetical moderate AD health state
(VAS scores divided by 100)
∗ Difference between current and hypothetical AD health
state is statistically signiﬁcant
EQ-5D health utility score and VAS
Figure 2: Current health state versus hypothetical moderate AD
state (weighted results).
(modeledasthediﬀerencebetweenutilityassociatedwiththe
current health state and the hypothetical AD health state),
age, gender, and a university background were signiﬁcant
variables. As age increases, the diﬀerence in health utility
score decreases between the current health state and the
hypothetical health state. Women compared to men, and
more educated participants, were more likely to perceive a
higher decrement in utility due to AD. Income, knowledge of
AD, or knowing someone with AD had no impact on utility
decrement. Results were similar for the unweighted regres-
sions.
4. Discussion
This pilot study demonstrates for the ﬁrst time that the
general public’s HRQoL ratings and health utility scores
are sensitive to AD as a disease entity. Severe reductions
in mobility, self-care, and usual activities, and increased
depression, were perceived when members of the general
public answered the EQ-5D under the assumption that they
had moderate AD. Mean utilities were also lower for mod-
erate AD relative to the current health state. Interestingly,
greaterknowledgeofADandknowingsomeonewithADdid
not inﬂuence the perception of AD, while age, gender, and
having a university diploma were signiﬁcant variables. This
may suggest that sociodemographics factors may be more
important than awareness of disease when the general public
is used as a proxy for assessing AD patients’ HRQoL.
This pilot study has several strengths. The participants
were recruited from a pan-Canadian sampling frame using
a random sampling methodology, thus eliminating selection
biases associated with region of residence or location of
recruitment.
Data from 500 individuals were collected with a stan-
dardized interview that was conducted by trained interview-
ers using CATI software to lessen potential information bias.
Of course, the limitations inherent in telephone surveys,
for example, a sample frame containing only persons who
have a home telephone number and nonresponse bias, alsoJournal of Aging Research 7
apply to our study. Our participants may be diﬀerent from
persons who were unreachable by telephone or unwilling to
participate.
Another issue regarding our study is the composition
of the sample, which may not be entirely representative of
the Canadian population. Since the sample was stratiﬁed by
income categories to minimize bias in determining levels
of support for a tax increase [30], we had to weight the
responses using Canadian income distributions. Minimal
diﬀerences were observed between the weighted and un-
weighted results, suggesting that the stratiﬁcation of our
sample was unlikely to have an impact on the results.
Our study was a pilot project using data collected to
answer an unrelated research question about support for a
tax increase to fund unrestricted access to AD medications
[30]. Thus, we were limited to assessing HRQoL using the
EQ-5D, which was the only HRQoL instrument employed
in the tax support study. We recognize the limitations of the
EQ-5D in assessing HRQoL from AD patients and caregiver
proxies [21, 22, 24]. However, one should note that the
EQ-5D has not been used with general public proxies to
estimate AD patients’ HRQoL. Our results suggest the EQ-
5D may be useful with general public proxies, although work
is needed to assess its test-retest reliability in the general
public. Due to our study design (e.g., telephone survey)
and time constraints, we did not use the standard gamble
or time trade-oﬀ techniques and it is currently unknown
to which extent these diﬀerent methods would diﬀer when
using the general public as a proxy for utility assessment in
AD. However, all methods (e.g., standard gamble or EQ-5D)
have in common that they ask respondents to imagine they
had moderate AD. Future research should compare utility
data derived from patients, caregivers, and general public.
In the tax support study, we collected data for proxy
ratings of moderate AD only. Future research needs to assess
the general public’s proxy ratings for mild and severe AD.
As well, we used the ADKT to examine participants’ level of
knowledge regarding AD. We realize the ADKT is dated, but
at the time of data collection (i.e., 2008), the ADKT was the
only test available to gauge what people knew about AD. In
the future, researchers surveying the general public may wish
to incorporate a newer instrument that became available
in 2009, that is, the Alzheimer’s Disease Knowledge Scale
[39]. The general public’s ratings on the EQ-5D may have
been inﬂuenced by the speciﬁc scenario we used to describe
moderate AD. Future research should test for “scenario
eﬀects” by utilizing more than one description of each AD
state and randomizing participants to receive diﬀerent sets of
descriptions.
Our pilot results cannot easily be compared to previous
studies because our work is the ﬁrst attempt to measure
utilities for a moderate AD health state using the general
public as a proxy. We did ﬁnd the health utility index score
associated with moderate AD in our study (i.e., 0.65) to
be similar to previous Canadian (i.e., 0.62) [22]a n dU S
(0.65) [24] ﬁndings where caregivers were used as proxies for
mild-to-moderate AD patients. Despite some of the afore-
mentioned issues with caregiver proxy ratings, the caregiver
ratingswereveryclosetothegeneralpublicratings.However,
more research needs to be undertaken to compare AD pa-
tients’ratingswithgeneralpublicandcaregiverproxyratings
to assess potential validity issues, for example, the possibility
of inverse correlations between patient ratings and general
public proxy ratings. Nonetheless, our results suggest that in
the absence of caregiver or patient data, the general public
could be used as proxy to elicit utility data that could be used
in decision analytic models comparing treatment options for
AD in terms of incremental cost per QALY gained.
5. Conclusions
Thisstudyistheﬁrstresearchprojectusingthegeneralpublic
to elicit HRQoL and health utility scores for moderate AD.
When utility is captured by the EQ-5D, the general public
believes that their utility would decrease by 0.235 if they
had moderate AD. This result suggests the general public
is sensitive to quality decrements in AD; members of the
general public may serve as an alternative to patients and
caregivers in the elicitation of HRQoL and heath utilities in
AD which could be used for economic evaluations. This is
important from a methodological perspective because there
are fewer barriers to conducting a telephone survey of a
random sample of the general public relative to recruiting a
sample of caregivers or AD suﬀerers.
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